Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Vianney Tricou, Delia Yu, Humberto Reynales, Shibadas Biswal, Xavier Saez-Llorens, Chukiat Sirivichayakul, Pio Lopez, Charissa Borja-Tabora, Lulu Bravo, Pope Kosalaraksa, Luis Martinez Vargas, Maria Theresa Alera, Luis Rivera, Veerachai Watanaveeradej, Reynaldo Dietze, LakKumar Fernando, V Pujitha Wickramasinghe, Edson Duarte Moreira, Asvini D Fernando, Dulanie Gunasekera, Kleber Luz, Ana Lucia Oliveira, Suely Tuboi, Ian Escudero, Yanee Hutagalung, Eric Lloyd, Martina Rauscher, Olaf Zent, Nicolas Folschweiller, Inge LeFevre, Felix Espinoza, Derek Wallace

Open source

DOI: 10.1016/s2214-109x(23)00522-3
Published: 2024-02
Container: The Lancet Global Health
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2214-109x-23-00522-3,
  title = {Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial},
  author = {Vianney Tricou and Delia Yu and Humberto Reynales and Shibadas Biswal and Xavier Saez-Llorens and Chukiat Sirivichayakul and Pio Lopez and Charissa Borja-Tabora and Lulu Bravo and Pope Kosalaraksa and Luis Martinez Vargas and Maria Theresa Alera and Luis Rivera and Veerachai Watanaveeradej and Reynaldo Dietze and LakKumar Fernando and V Pujitha Wickramasinghe and Edson Duarte Moreira and Asvini D Fernando and Dulanie Gunasekera and Kleber Luz and Ana Lucia Oliveira and Suely Tuboi and Ian Escudero and Yanee Hutagalung and Eric Lloyd and Martina Rauscher and Olaf Zent and Nicolas Folschweiller and Inge LeFevre and Felix Espinoza and Derek Wallace},
  year = {2024},
  journal = {The Lancet Global Health},
  doi = {10.1016/s2214-109x(23)00522-3},
  url = {https://doi.org/10.1016/s2214-109x(23)00522-3}
}

RIS

TY  - JOUR
TI  - Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial
AU  - Vianney Tricou
AU  - Delia Yu
AU  - Humberto Reynales
AU  - Shibadas Biswal
AU  - Xavier Saez-Llorens
AU  - Chukiat Sirivichayakul
AU  - Pio Lopez
AU  - Charissa Borja-Tabora
AU  - Lulu Bravo
AU  - Pope Kosalaraksa
AU  - Luis Martinez Vargas
AU  - Maria Theresa Alera
AU  - Luis Rivera
AU  - Veerachai Watanaveeradej
AU  - Reynaldo Dietze
AU  - LakKumar Fernando
AU  - V Pujitha Wickramasinghe
AU  - Edson Duarte Moreira
AU  - Asvini D Fernando
AU  - Dulanie Gunasekera
AU  - Kleber Luz
AU  - Ana Lucia Oliveira
AU  - Suely Tuboi
AU  - Ian Escudero
AU  - Yanee Hutagalung
AU  - Eric Lloyd
AU  - Martina Rauscher
AU  - Olaf Zent
AU  - Nicolas Folschweiller
AU  - Inge LeFevre
AU  - Felix Espinoza
AU  - Derek Wallace
PY  - 2024
JO  - The Lancet Global Health
DO  - 10.1016/s2214-109x(23)00522-3
UR  - https://doi.org/10.1016/s2214-109x(23)00522-3
ER  -

APA

Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., Vargas, L. M., Alera, M. T., Rivera, L., Watanaveeradej, V., Dietze, R., Fernando, L., Wickramasinghe, V. P., Moreira, E. D., Fernando, A. D., Gunasekera, D., Luz, K., Oliveira, A. L., Tuboi, S., Escudero, I., Hutagalung, Y., Lloyd, E., Rauscher, M., Zent, O., Folschweiller, N., LeFevre, I., Espinoza, F., & Wallace, D. (2024). Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(23)00522-3

Source records

crossref · retrieved 2026-09-27T14:04:49.261Z